China Releases List To Encourage Competition
Executive Summary
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
You may also be interested in...
China Dodges Chance To Impose Linkage And Exclusivity
Patent-linkage and data exclusivity changes have not been implemented in a major overhaul of medicines law in China. But they could still come through patent law updates.
Cipla Docks Into China With Manufacturing Plans In Tow
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
Alembic Charts China Plans, Sees Price Cuts As No Dampener
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.